Ipilimumab: its potential in non-small cell lung cancer

Ipilimumab is a fully human monoclonal antibody that enhances antitumor immunity by way of cytotoxic T-lymphocyte antigen 4 blockade. It has already been approved by the US Food and Drug Administration for the treatment of metastatic melanoma and is being investigated for treating other solid tumors...

Full description

Bibliographic Details
Main Authors: Pascale Tomasini, Nataliya Khobta, Laurent Greillier, Fabrice Barlesi
Format: Article
Language:English
Published: SAGE Publishing 2012-03-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758834011431718
_version_ 1828836754509004800
author Pascale Tomasini
Nataliya Khobta
Laurent Greillier
Fabrice Barlesi
author_facet Pascale Tomasini
Nataliya Khobta
Laurent Greillier
Fabrice Barlesi
author_sort Pascale Tomasini
collection DOAJ
description Ipilimumab is a fully human monoclonal antibody that enhances antitumor immunity by way of cytotoxic T-lymphocyte antigen 4 blockade. It has already been approved by the US Food and Drug Administration for the treatment of metastatic melanoma and is being investigated for treating other solid tumors such as renal cell, prostate and lung cancers. This review details the potential of ipilimumab in the management of non-small cell lung cancer (NSCLC). In particular, ipilimumab showed promising results in a first-line NSCLC phase II study combining carboplatin/paclitaxel chemotherapy with concurrent or phased ipilimumab. The median immune-related progression-free survival was 5.68 months for the phased ipilimumab arm versus 4.63 months for chemotherapy alone (hazard ratio [HR] = 0.68, p = 0.026) and 5.52 months for the concurrent ipilimumab arm versus 4.63 months for chemotherapy alone (HR = 0.77, p = 0.094). The main adverse events were immune related, such as hypophysitis, enterocolitis, and hyperthyroidism. These adverse events may be improved with high-dose glucocorticoids and may be correlated with tumor response. Phase III studies are ongoing. Future studies may investigate ipilimumab in the management of early stage lung cancer. Strategies for potential translational research studies are also discussed to identify prognostic and predictive biomarkers for the use of ipilimumab in the treatment of patients with NSCLC.
first_indexed 2024-12-12T18:27:35Z
format Article
id doaj.art-1c3c0e5f366e4378a0961fc1a1d9a352
institution Directory Open Access Journal
issn 1758-8340
1758-8359
language English
last_indexed 2024-12-12T18:27:35Z
publishDate 2012-03-01
publisher SAGE Publishing
record_format Article
series Therapeutic Advances in Medical Oncology
spelling doaj.art-1c3c0e5f366e4378a0961fc1a1d9a3522022-12-22T00:16:00ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83401758-83592012-03-01410.1177/1758834011431718Ipilimumab: its potential in non-small cell lung cancerPascale TomasiniNataliya KhobtaLaurent GreillierFabrice BarlesiIpilimumab is a fully human monoclonal antibody that enhances antitumor immunity by way of cytotoxic T-lymphocyte antigen 4 blockade. It has already been approved by the US Food and Drug Administration for the treatment of metastatic melanoma and is being investigated for treating other solid tumors such as renal cell, prostate and lung cancers. This review details the potential of ipilimumab in the management of non-small cell lung cancer (NSCLC). In particular, ipilimumab showed promising results in a first-line NSCLC phase II study combining carboplatin/paclitaxel chemotherapy with concurrent or phased ipilimumab. The median immune-related progression-free survival was 5.68 months for the phased ipilimumab arm versus 4.63 months for chemotherapy alone (hazard ratio [HR] = 0.68, p = 0.026) and 5.52 months for the concurrent ipilimumab arm versus 4.63 months for chemotherapy alone (HR = 0.77, p = 0.094). The main adverse events were immune related, such as hypophysitis, enterocolitis, and hyperthyroidism. These adverse events may be improved with high-dose glucocorticoids and may be correlated with tumor response. Phase III studies are ongoing. Future studies may investigate ipilimumab in the management of early stage lung cancer. Strategies for potential translational research studies are also discussed to identify prognostic and predictive biomarkers for the use of ipilimumab in the treatment of patients with NSCLC.https://doi.org/10.1177/1758834011431718
spellingShingle Pascale Tomasini
Nataliya Khobta
Laurent Greillier
Fabrice Barlesi
Ipilimumab: its potential in non-small cell lung cancer
Therapeutic Advances in Medical Oncology
title Ipilimumab: its potential in non-small cell lung cancer
title_full Ipilimumab: its potential in non-small cell lung cancer
title_fullStr Ipilimumab: its potential in non-small cell lung cancer
title_full_unstemmed Ipilimumab: its potential in non-small cell lung cancer
title_short Ipilimumab: its potential in non-small cell lung cancer
title_sort ipilimumab its potential in non small cell lung cancer
url https://doi.org/10.1177/1758834011431718
work_keys_str_mv AT pascaletomasini ipilimumabitspotentialinnonsmallcelllungcancer
AT nataliyakhobta ipilimumabitspotentialinnonsmallcelllungcancer
AT laurentgreillier ipilimumabitspotentialinnonsmallcelllungcancer
AT fabricebarlesi ipilimumabitspotentialinnonsmallcelllungcancer